Résultats de la recherche
10
Tout
Rechercher les filtres
Mot-clé
adhd
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
26 mars 2025 17h00 HE
|
Cingulate Inc.
In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025$17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for...
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
04 mars 2025 09h00 HE
|
Cingulate Inc.
Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily Stimulant Medication to Treat ADHD Over the Entire Active Day KANSAS CITY,...
Focus ADHD Launches Virtual ADHD Clinic for Florida Professionals, Now Serving Hialeah and the Greater Miami Area
31 janv. 2025 09h00 HE
|
Focus ADHD Miami
Miami, Florida, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Focus ADHD Miami, a pioneering virtual psychiatric clinic, today announced the expansion of its specialized adult ADHD treatment services across...
NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental Disorders
22 janv. 2025 09h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 22, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for...
Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment
13 janv. 2025 09h00 HE
|
NeuroSigma, Inc.
ATTENS (ADHD trial of external trigeminal nerve stimulation) Project, led by Professor Katya Rubia at the Institute of Psychiatry, Psychology & Neuroscience is a multicentre, double-blind,...
Final Study Completed for Cingulate’s Lead Asset CTx-1301
07 janv. 2025 07h30 HE
|
Cingulate Inc.
No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025 KANSAS CITY, Kan., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000
23 déc. 2024 07h30 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark’s Center for Evidence-Based Psychiatry
11 déc. 2024 09h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced today that the Center for Evidence-Based Psychiatry (CEBP) in Denmark has...
ADHD: What You Need to Know
19 nov. 2024 10h00 HE
|
Brain & Behavior Research Foundation
New York, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Attention-Deficit Hyperactivity Disorder (ADHD) is one of the most common mental health disorders of childhood. On Wednesday, December 4, 2024, at 7 p.m....
Annual International Conference on ADHD Hosted by CHADD, ADDA and ACO Provides Trusted Information, Guidance and Support to the ADHD Community
07 nov. 2024 08h00 HE
|
Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD)
The Annual International Conference on ADHD 2024, hosted by CHADD, ADDA and ACO, will be held November 14 through 16 in Anaheim, California.